MGV354 / Novartis - LARVOL DELTA

Understanding metabolism related differences in ocular efficacy of MGV354. (PubMed, Xenobiotica) - "There were no observable interspecies differences in the hepatic and ocular metabolism of MGV354. Although ocular metabolism was not as extensive as hepatic, the results do not explain the lack of efficacy of MGV354 in clinical studies."

Clinical • Journal • Glaucoma • Hypertension • Ophthalmology • sGC HDA+

"Live at #ARVO2018 NIBR present good IOP-lowering data for sGC activator MGV-354 in NHP" (@Cortellis)

Biosimilar

A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma. (PubMed, Am J Ophthalmol) - P1/2; "Overall, MGV354 0.1% demonstrated no statistically significant effect compared to Vehicle in lowering IOP based upon the study's main outcome measure. MGV354 produced ocular hyperemia consistent with its pharmacology."

Clinical • Journal • P1/2 data